Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

Trial Identifier: D3250R00113
Sponsor: AstraZeneca
Start Date: February 2023
Primary Completion Date: April 2025
Study Completion Date: April 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Colombia Bogota, Colombia
Colombia Bucaramanga, Colombia
Colombia Ibague, Colombia
Colombia Pereira, Colombia
Dominican Republic Santiago, Dominican Republic
Dominican Republic Santo Domingo, Dominican Republic
India Ahmedabad, India
India Ajmer, India
India Chennai, India
India Delhi, India
India Hyderabad, India
India Jaipur, India
India Kolkata, India
India Pune, India
India Secundrabad, India
India Vadodara, India
Kuwait Sabah Al Salem, Kuwait
Oman Muscat, Oman
Qatar Doha, Qatar
Saudi Arabia Jeddah, Saudi Arabia
Saudi Arabia Riyadh, Saudi Arabia
United Arab Emirates Abu Dhabi, United Arab Emirates
United Arab Emirates Al Ain, United Arab Emirates
United Arab Emirates Dubai, United Arab Emirates